Related Experiment Video
Updated: Jun 21, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma
Coen J Lap1, James Di Palma-Grisi2, Andrew Ip2
1Division of Hematology, Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, District of Columbia, USA.
Hematological Oncology
|June 19, 2026
Summary
Two patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) achieved complete remission with glofitamab. This bispecific antibody offers a promising new treatment option for patients with difficult-to-treat PCNSL.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Hematology
Background:
- Primary central nervous system lymphoma (PCNSL) often relapses or becomes refractory to standard therapies.
- Limited effective treatment options exist for patients with relapsed/refractory (R/R) PCNSL, leading to a poor prognosis.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...